Trypanosomiasis vaccine
A Trypanosomiasis vaccine is a vaccine against trypanosomiasis. No effective vaccine currently exists, but development of a vaccine is the subject of current research.
The Bill & Melinda Gates Foundation has been involved in funding research conducted by the Sabin Vaccine Institute and others.[1]
There are many obstacles to development of such a vaccine. One obstacle is variant surface glycoprotein which makes it difficult for the immune system to recognize the infectious organism.[2] Also, Trypanosoma brucei has a direct inhibitory effect upon B cells.[3]
It has been suggested that these challenges could be overcome by a vaccine against the initial antigens,[4] or generating an immune response against the cysteine protease (for example, cruzipain).[5][6]
An effective vaccine was achieved in 2021 using a mouse model of infection with Trypanosoma vivax.[7]
See also
References
- ^ "US Fraunhofer Center receives Grant from the Bill & Melinda Gates Foundation-Intellectual Property". Retrieved 2009-01-15.
- PMID 18936180.
- PMID 18516300.
- ^ "Trypanosomiasis". Retrieved 2009-01-15.
- S2CID 22315392.
- PMID 11595229.
- PMID 34040257.